SEARCH

SEARCH BY CITATION

References

  • 1
    Waggoner SE. Cervical cancer. Lancet 2003; 361: 221725.
  • 2
    Garzetti GG, Ciavattini A, Lucarini G, Goteri G, De Nictolis M, Biagini G. Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol 1996; 61: 197203.
  • 3
    Nuovo GJ, MacConnell PB, Simsir A, Valea F, French DL. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55: 26775.
  • 4
    Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, Foidart JM. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 1996; 65: 20913.
  • 5
    Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, Uehira M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999; 17: 17781.
  • 6
    Iwasaki M, Nishikawa A, Fujimoto T, Akutagawa N, Manase K, Endo T, Yoshida K, Maekawa R, Yoshioka T, Kudo R. Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol 2002; 85: 1037.
  • 7
    Brummer O, Bohmer G, Hollwitz B, Flemming P, Petry KU, Kuhnle H. MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation––an immunohistochemical study. Gynecol Oncol 2002; 84: 2227.
  • 8
    Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, Hsu SM. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003; 63: 653742.
  • 9
    Kato Y, Yamashita T, Ishikawa M. Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep 2002; 9: 5659.
  • 10
    Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben Baruch G, Reich R. MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma––a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999; 73: 37282.
  • 11
    Moser PL, Kieback DG, Hefler L, Tempfer C, Neunteufel W, Gitsch G. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer. Anticancer Res 1999; 19: 43913.
  • 12
    Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22: 20522.
  • 13
    Barmina OY, Walling HW, Fiacco GJ, Freije JM, Lopez-Otin C, Jeffrey JJ, Partridge NC. Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization. J Biol Chem 1999; 274: 3008793.
  • 14
    Seiki M, Koshikawa N, Yana I. Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Metastasis Rev 2003; 22: 12943.
  • 15
    Guo H, Li R, Zucker S, Toole BP. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 2000; 60: 88891.
  • 16
    Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003; 22: 15366.
  • 17
    Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 27382.
  • 18
    Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N, Danø K. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996; 65: 5762.
  • 19
    Zucker S, Hymowitz M, Rollo EE, Mann R, Conner CE, Cao J, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol 2001; 158: 19218.
  • 20
    Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997; 272: 247.
  • 21
    Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, Birembaut P. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002; 19: 697702.
  • 22
    Malina R, Motoyama S, Hamana S, Maruo T. Laminin-5 γ2 chain and matrix metalloproteinase-2 expression in the neoplastic changes of uterine cervical squamous epithelium. Kobe J Med Sci 2004; 50: 12330.
  • 23
    Nagase H. Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res 1998; 8: 17986.
  • 24
    Hazelbag S, Gorter A, Kenter GG, Van Den Broek L, Fleuren G. Transforming growth factor-β1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. Hum Pathol 2002; 33: 11939.
  • 25
    Ruiter DJ, Ferrier CM, van Muijen GN, Henzen-Logmans SC, Kennedy S, Kramer MD, et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 concerted action on clinical relevance of proteases in tumour invasion and metastasis. Eur J Cancer 1998; 34: 133440.
  • 26
    de Boer WI, van Schadewijk A, Sont JK, Sharma HS, Stolk J, Hiemstra PS, van Krieken JH. Transforming growth factor β1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 19517.
  • 27
    Bisson C, Blacher S, Polette M, Blanc JF, Kebers F, Desreux J, et al. Restricted expression of membrane type 1-matrix metalloproteinase by myofibroblasts adjacent to human breast cancer cells. Int J Cancer 2003; 105: 713.
  • 28
    Mook OR, Van Overbeek C, Ackema EG, Van Maldegem F, Frederiks WM. In situ localization of gelatinolytic activity in the extracellular matrix of metastases of colon cancer in rat liver using quenched fluorogenic DQ-gelatin. J Histochem Cytochem 2003; 51: 8219.
  • 29
    Barth PJ, Ramaswamy A, Moll R. CD34(+) fibrocytes in normal cervical stroma, cervical intraepithelial neoplasia III, and invasive squamous cell carcinoma of the cervix uteri. Virchows Arch 2002; 441: 5648.
  • 30
    Rudek MA, Venitz J, Figg WD. Matrix metalloproteinase inhibitors: do they have a place in anticancer therapy? Pharmacotherapy 2002; 22: 70520.
  • 31
    Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61: 23742.
  • 32
    Stock RJ, Zaino R, Bundy BN, Askin FB, Woodward J, Fetter B, et al. Evaluation and comparison of histopathologic grading systems of epithelial carcinoma of the uterine cervix: Gynecologic Oncology Group studies. Int J Gynecol Pathol 1994; 13: 99108.
  • 33
    Chattopadhyay N, Mitra A, Frei E, Chatterjee A. Human cervical tumor cell (SiHa) surface αvβ3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity. J Cancer Res Clin Oncol 2001; 127: 6538.
  • 34
    Smola-Hess S, Pahne J, Mauch C, Zigrino P, Smola H, Pfister HJ. Expression of membrane type 1 matrix metalloproteinase in papillomavirus-positive cells: role of the human papillomavirus (HPV) 16 and HPV8 E7 gene products. J Gen Virol 2005; 86: 12916.
  • 35
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 16174.
  • 36
    Overall CM, McQuibban GA, Clark-Lewis I. Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics. Biol Chem 2002; 383: 105966.
  • 37
    Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F, Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 105967.
  • 38
    Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor α, interleukin 1 and phorbol ester. Biochem J 1993; 296(Pt 3): 8039.
  • 39
    Suzuki S, Sato M, Senoo H, Ishikawa K. Direct cell-cell interaction enhances pro-MMP-2 production and activation in co-culture of laryngeal cancer cells and fibroblasts: involvement of EMMPRIN and MT1-MMP. Exp Cell Res 2004; 293: 25966.